The applicant, a pharmaceutical manufacturer, sought judicial review of a recommendation by the Canadian Agency for Drugs and Technologies in Health (CADTH).
The applicant alleged that CADTH breached its duty of procedural fairness by failing to publish draft rules for a pilot project and by allowing a competitor to participate, thereby giving the competitor an unfair market advantage.
The Divisional Court dismissed the application, finding that CADTH had widely communicated the existence of the pilot project to the industry and that any manufacturer, including the applicant, could have volunteered to participate.
The court concluded that CADTH's conduct was transparent, even-handed, and reasonable, and that there was no breach of the applicant's legitimate expectations.